Blueprint Medicines (NASDAQ:BPMC) insider Marion Dorsch sold 2,300 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $100.07, for a total transaction of $230,161.00. Following the completion of the transaction, the insider now owns 2,300 shares of the company’s stock, valued at approximately $230,161. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Blueprint Medicines stock opened at $93.29 on Wednesday. Blueprint Medicines has a 12 month low of $34.38 and a 12 month high of $109.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.98 and a quick ratio of 15.98.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.16). The firm had revenue of $1.63 million during the quarter, compared to analyst estimates of $5.28 million. Blueprint Medicines had a negative net margin of 691.30% and a negative return on equity of 38.79%. The business’s quarterly revenue was down 78.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) earnings per share. equities research analysts anticipate that Blueprint Medicines will post -4.85 earnings per share for the current fiscal year.
A number of research analysts recently issued reports on the stock. BidaskClub downgraded shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Friday, February 23rd. Finally, Cowen reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $84.20.
Institutional investors and hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new position in Blueprint Medicines in the 3rd quarter valued at $6,967,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Blueprint Medicines by 57.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 680 shares in the last quarter. California Public Employees Retirement System purchased a new stake in shares of Blueprint Medicines during the 2nd quarter worth $314,000. Virtus Fund Advisers LLC purchased a new stake in shares of Blueprint Medicines during the 4th quarter worth $348,000. Finally, Geode Capital Management LLC boosted its position in shares of Blueprint Medicines by 10.6% during the 4th quarter. Geode Capital Management LLC now owns 369,391 shares of the biotechnology company’s stock worth $27,855,000 after purchasing an additional 35,455 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.
About Blueprint Medicines
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.